Comparing two drug combos for advanced colorectal cancer (second-line)
Part of Cancer, Digestive system clinical trials.
This trial tests if a newer targeted drug (fruquintinib) works as well as a standard drug (bevacizumab) when combined with two chemotherapy drugs for people with advanced colorectal cancer that got worse after first treatment. It aims to find a better option for second-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread and gotten worse after one prior treatment (or within 6 months of finishing adjuvant chemo).
- You are between 18 and 75 years old.
- You are in good enough health to get around and care for yourself (ECOG score 0-1).
- You have not received irinotecan or a small-molecule anti-angiogenic targeted therapy before.
- Your blood counts, liver, and kidney function are within acceptable ranges (routine lab tests will confirm).
- You are not pregnant and agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial compares two drug combinations for patients whose colorectal cancer has spread and worsened after first treatment. You would receive either FOLFOX or FOLFIRI plus fruquintinib, or the same chemo plus bevacizumab, to see which works better.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.